Antibody molecules which bind CD22
The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
1. An antibody molecule comprising a binding domain specific to CD22, wherein the binding domain comprises a heavy chain variable domain (VH) comprising CDR H1, CDR H2, and CDR H3 and a light chain variable domain (VL) comprising CDR V1, CDR V2, and CDR V3 wherein
CDR H1 is SEQ ID NO: 37;
CDR H2 is SEQ ID NO: 48, 49, 50, 51, 52 or 53;
CDR H3 is SEQ ID NO: 65, 66 or 67;
CDR L1 is SEQ ID NO: 73;
CDR L2 is SEQ ID NO: 79; and
CDR L3 is SEQ ID NO: 100.
2. The antibody molecule according to claim 1 , wherein VH and VL are humanised.
3. The antibody molecule according to claim 2 wherein the VH comprises a human framework region wherein at least one position in the heavy chain human framework is selected from the group consisting of position 11 is leucine, position 23 is lysine, position 24 is alanine or glycine, position 37 is valine, position 47 is leucine, position 48 is isoleucine, valine or serine, position 49 is alanine or glycine, position 67 is phenylalanine or valine, position 71 is lysine or asparagine, position 73 is serine, position 76 is threonine, position 78 is valine and position 94 is arginine and/or the VL comprises a human framework region wherein at least one position in the light chain human framework is selected from the group consisting of position 1 is alanine, position 2 is phenylalanine or alanine, position 3 is valine or glutamic acid, position 36 is phenylalanine, position 63 is lysine, position 65 is aspartic acid, position 66 is arginine, position 70 is glutamine, and position 71 is tyrosine, numbering according to Kabat.
4. The antibody molecule according to claim 1 , comprising a VH comprising SEQ ID NO: 146.
5. The antibody molecule according to claim 1 , comprising a VL comprising SEQ ID NO:144.
6. A composition comprising one or more antibody molecules as defined in claim 1 .
7. An antibody molecule comprising a VH comprising SEQ ID NO: 146.